# INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

> **NCT02474537** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** INC280

## Key facts

- **NCT ID:** NCT02474537
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-12
- **Primary completion:** 2017-08-14
- **Final completion:** 2017-09-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474537, "INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02474537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*